NSI-189 Freebase Powder

NSI-189 Freebase Powder

Introduction

NSI-189 Freebase is a meticulously formulated research product designed explicitly for scientific exploration and strictly excludes human consumption. This freebase form of NSI-189 serves as a valuable tool for researchers investigating its unique properties and potential benefits across various research domains.

Key Characteristics

NSI-189 Freebase is a derivative of benzylpiperazine, known for its potential impact on neuroregeneration and cognitive function. As a member of the nootropic class, it has become a focus of research due to its potential pro-cognitive effects.

Research Applications

NSI-189 Freebase has versatile applications in research, providing researchers with a tool to investigate its potential benefits. Its applications extend to studies on major depressive disorder, pro-cognitive efficacy, and its potential role in stroke recovery.

Research Benefits

NSI-189 Freebase and Major Depressive Disorder

Studies suggest that NSI-189 Freebase may have potential applications for major depressive disorder (MDD). Research in this area aims to understand its mechanisms of action and potential therapeutic applications in treating depressive disorders.

NSI-189 Freebase and Pro-Cognitive Efficacy

Preliminary research suggests that NSI-189 Freebase may enhance cognitive function, potentially improving memory and overall cognitive performance. Investigations into its cognitive enhancement effects contribute to understanding its potential applications in supporting cognitive processes.

NSI-189 Freebase and Stroke

Research suggests that NSI-189 Freebase may have implications for stroke recovery, potentially supporting neuroregeneration and functional recovery after stroke. Studies exploring its effects on stroke-related conditions contribute to understanding its potential applications in neurorehabilitation.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our content is carefully designed to provide research-oriented insights and should not replace independent analysis and verification from credible sources before making purchasing decisions.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human use.

References

• Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double-blind, placebo-controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. PMID: 26643541; PMCID: PMC5030464.
• McIntyre RS, Johe K, Rong C, Lee Y. The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects. Expert Opin Investig Drugs. 2017 Jun;26(6):767-770. doi: 10.1080/13543784.2017.1324847. PMID: 28460574.
• Tajiri N, Quach DM, Kaneko Y, Wu S, Lee D, Lam T, Hayama KL, Hazel TG, Johe K, Wu MC, Borlongan CV. NSI-189, a small molecule with neurogenic properties, exerts behavioral and neurostructural benefits in stroke rats. J Cell Physiol. 2017 Oct;232(10):2731-2740. doi: 10.1002/jcp.25847. PMID: 28181668; PMCID: PMC5518191.